Clinical Trial
Product Study No. identifier Phase Study Description Status
SYN004 SYN004-001 NCT02391727 I Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors(American trial) Ongoing
SYN023 SYN023-001 NA I Evaluation of the Safety, Tolerability, Pharmacokinetics and Neutralizing Activity of Single, Escalating, Intramuscular Injection Doses of SYN023 in Healthy Adult Volunteers. Completed
SYN023 SYN023-002 NCT02956746 II A Phase 2 randomized blinded single dose comparison of the safety, pharmacokinetics, and pharmacodynamics of rabies immune globulin, and SYN023 in healthy adult subjects receiving rabies vaccines Completed
SYN008 S08-01 NA I A Phase I randomized blinded single dose comparison of the safety pharmacokinetics and pharmacodynamics of SYN008 and omalizumab (Xolair) in healthy adult subjects Ongoing
SYN050 160045 NA I Randomized, double-blind, parallel study evaluating the pharmacokinetic similarity of SYN050 (Synermore biologics bevacizumab) and Avastin, following a single i.v. dose of 2 mg/kg in healthy male volunteers(New Zealand Trial) Ongoing
SYN060 SYN060-001 NCT03254810 I A phase 1 comparison evaluation of safety and pharmacokinetics between SYN060 and Adalimumab (Humira) in healthy adults subjects (Australian trial) Ongoing
SYN023 SYN023-003 NA Ib A phase 1 evaluation of the safety, pharmacokinetics and pharmacodynamics of single intramuscular and subcutaneous doses of SYN023 in healthy adult subjects(American trial) Completed
SYN023 SYN023-005 NA Ia/Ib A phase I bridging clinical trial of safety, pharmacokinetics and pharmacodynamics of single-center, open, randomized single intramuscular dose of SYN023 in healthy adult subjects(Chinese Trial) Ongoing
SYN004 RG01N-1829 NA Ia A phase I clinical trial of tolerability, pharmacokinetics and safety of SYN004 with solid tumors(Chinese Trial) Ongoing